# Execution Scorecard: Women's health radar

Score: 65/100

Tier: Needs focused validation

Women's health radar scores 65/100 for execution readiness. The recommended next step is Run a 4-6 week landing-page plus waitlist test targeting women 40-55 with a free 'perimenopause symptom radar' quiz built on a validated scale; measure quiz completion, opt-in to weekly tracking, and click-through to a (simulated) clinician-summary or telehealth referral. A signal worth funding is >25% of quiz completers opting into ongoing tracking and >10% requesting the clinician summary or referral.

## Bottlenecks
- Medical-claims and regulatory risk: surfacing 'early signals' can be read as diagnosis; the app must avoid FDA SaMD/medical-device classification and frame outputs as education, with clear disclaimers and clinician review.
- Well-funded incumbents (Midi Health, Balance, Caria, Health & Her) already own symptom tracking and care delivery, so a pure tracker risks being a feature, not a company.
- Health data privacy obligations (HIPAA when integrated with covered entities, plus state reproductive/health-data laws) raise compliance cost and liability for sensitive symptom data.
- Retention is hard: menopause symptom tracking has high churn once acute symptoms resolve, threatening subscription LTV unless tied to ongoing care.
- A broad AI assistant can flatten differentiation unless the wedge is painfully specific.
- The first release can become a generic dashboard if the job is not named tightly.
- Needs real buyer access, not only desk research.

## Accelerators
- Can talk to the buyer before writing much code.
- Can ship a narrow first-win demo quickly.
- Can use local-first research artifacts to keep validation moving without a large team.
- Use specificity as the wedge: one buyer, one workflow, one measurable result.
- Show proof earlier than broad competitors with before-and-after examples and small pilot data.
- Keep implementation lighter than incumbent suites or generic AI assistants.
- Concierge review or paid template

## Dated Launch Plan
- **2026-07-07 / Frame the wedge**: Write the one-sentence promise and test it in the strongest channel. Proof: Run a 4-6 week landing-page plus waitlist test targeting women 40-55 with a free 'perimenopause symptom radar' quiz built on a validated scale; measure quiz completion, opt-in to weekly tracking, and click-through to a (simulated) clinician-summary or telehealth referral. A signal worth funding is >25% of quiz completers opting into ongoing tracking and >10% requesting the clinician summary or referral.
- **2026-07-10 / Interview 10 people who match the buyer persona.**: Create the lead magnet and use it to recruit interviews. Proof: Problem resonance: 5+ calls or 10+ detailed replies.
- **2026-07-14 / Ship a clickable demo or concierge workflow that produces the first useful artifact.**: Build the smallest demo that proves the first win. Proof: Activation: 25% of demo visitors complete the first-win path.
- **2026-07-21 / Run one paid pilot or collect explicit pricing objections before automating the rest.**: Delete any report section that feels generic before building. Proof: Commercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.
- **2026-07-28 / Promote to a deeper build plan only after the wedge survives validation.**: Run the lead magnet and first-win demo tests. Proof: Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.
- **2026-08-06 / Execution checkpoint 6**: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach. Proof: Promote to a deeper build plan only after the wedge survives validation.

## Builder Prompt
Create a dated execution plan for "Women's health radar". Keep the first milestone tied to Run a 4-6 week landing-page plus waitlist test targeting women 40-55 with a free 'perimenopause symptom radar' quiz built on a validated scale; measure quiz completion, opt-in to weekly tracking, and click-through to a (simulated) clinician-summary or telehealth referral. A signal worth funding is >25% of quiz completers opting into ongoing tracking and >10% requesting the clinician summary or referral.. Use these bottlenecks: Medical-claims and regulatory risk: surfacing 'early signals' can be read as diagnosis; the app must avoid FDA SaMD/medical-device classification and frame outputs as education, with clear disclaimers and clinician review.; Well-funded incumbents (Midi Health, Balance, Caria, Health & Her) already own symptom tracking and care delivery, so a pure tracker risks being a feature, not a company.; Health data privacy obligations (HIPAA when integrated with covered entities, plus state reproductive/health-data laws) raise compliance cost and liability for sensitive symptom data.; Retention is hard: menopause symptom tracking has high churn once acute symptoms resolve, threatening subscription LTV unless tied to ongoing care.; A broad AI assistant can flatten differentiation unless the wedge is painfully specific.; The first release can become a generic dashboard if the job is not named tightly.; Needs real buyer access, not only desk research.. Use these accelerators: Can talk to the buyer before writing much code.; Can ship a narrow first-win demo quickly.; Can use local-first research artifacts to keep validation moving without a large team.; Use specificity as the wedge: one buyer, one workflow, one measurable result.; Show proof earlier than broad competitors with before-and-after examples and small pilot data.; Keep implementation lighter than incumbent suites or generic AI assistants.; Concierge review or paid template. Link the output to the Idea Builder prompt and do not expand beyond the first validated workflow.